Nordicus Partners furnishes independent valuations for Orocidin and Bio-Convert subsidiaries

Nordicus Partners Corp

Stanton Park Advisors LLC prepared valuation reports for Orocidin's QR-01 and Bio-Convert's QR-02 as of June 30, 2025.
The valuations are intended for Board evaluation of fair market value and should not be relied upon for other purposes.
No specific valuation figures are disclosed in the filing; exhibits are placeholders only.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.